Centessa Pharmaceuticals

CNTA

Market cap $3.97B

Commodore Capital sold 1,850,000 shares of Centessa in the fourth quarter; the estimated trade value was $46.86 million. Meanwhile, the quarter-end position value decreased by $44.10 million, reflecting both trading and price changes.

Connecticut-based Braidwell initiated a position of 2,188,320 Centessa shares in the fourth quarter. The quarter-end value of the position increased by $54.73 million, reflecting the new stake.

Tokyo, Japan and Cambridge, UK, 12 February 2026 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) today notes that Centessa Pharmaceuticals has achieved an early development milestone associated with its investigational, orally administered, highly potent and selective orexin receptor 2 (OX2R) agonist, ORX489, being developed by Centessa for the treatment of neuropsychiatric disorders. This milestone triggers a payment of US$1.8 million to Nxera pursuant to its research collaboration with Centessa. The milestone payment will be recognized as revenue in the first quarter of 2026.

BOSTON and LONDON, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to discover and develop transformational medicines for patients, today announced that members of its management team will participate in the following investor conferences: Event: Guggenheim Emerging Outlook: Biotech Summit Date: Thursday, February 12, 2026 Fireside Chat: 1:00 PM ET Event: TD Cowen 46th Annual Health Care Conference Date: Tuesday, March 3, 2026 Fireside Chat: 3:10 PM ET Event: Leerink Partners Global Healthcare Conference Date: Tuesday, March 10, 2026 Fireside Chat: 8:00 AM ET Event: Jefferies Biotech on the Beach Summit Date: Wednesday, March 11, 2026 Where available, access to the live webcasts of these events, as well as archived recordings, will be posted under the “Events and Publications” tab on the investor relations section of the Centessa Pharmaceuticals website at https://investors.centessa.com/events-presentations. About Centessa Pharmaceuticals Centessa Pharmaceuticals, plc is a clinical-stage pharmaceutical company with a mission to discover, develop and ultimately deliver medicines that are transformational for patients.

Tanager Wealth Management exited its entire CNTA position, reducing holdings by 598,044 shares in the fourth quarter. As a result, the quarter-end position value decreased by $14.50 million, reflecting both the share sale and stock price movement.

Antidepressive effects and enhanced wakefulness were observed with OX2R activation in established animal model of major depressive disorder Antidepressive effects and enhanced wakefulness were observed with OX2R activation in established animal model of major depressive disorder

Tokyo, Japan and Cambridge, UK, 13 January 2026 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) notes that Centessa Pharmaceuticals has achieved an early development milestone associated with its investigational, orally administered, highly potent and selective orexin receptor 2 (OX2R) agonist, ORX142, in development for the treatment of neurological and neurodegenerative disorders. This milestone triggers a payment of US$3.6 million to Nxera pursuant to its research collaboration with Centessa. The milestone payment will be recognised as revenue in Q4 FY2025.

Mario Alberto Accardi PhD, President and founder of Centessa's Orexin Program, appointed Chief Executive Officer and member of the Board of Directors Mario Alberto Accardi PhD, President and founder of Centessa's Orexin Program, appointed Chief Executive Officer and member of the Board of Directors

San Francisco-based 5AM Venture Management sold 150,000 CNTA shares in the third quarter. Despite the sale, the stock's sharp rally last quarter led the fund's net position value in CNTA to increase by $5.6 million.

California-based TCG Crossover Management increased its stake in Centessa Pharmaceuticals by 245,664 shares in the third quarter for an estimated $38.1 million. The transaction value equaled about 0.2% of the fund's 13F reportable assets under management (AUM) at quarter-end.